Ginkgo Bioworks
27 Drydock Avenue
8th Floor
Boston
Massachusetts
02210
United States
Tel: 814-HACK-DNA
Website: http://ginkgobioworks.com/
255 articles about Ginkgo Bioworks
-
bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network
2/28/2024
bit.bio, the company coding human cells for novel cures, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced bit.bio as an inaugural partner of the Ginkgo Technology Network.
-
Ginkgo Technology Network Launches, Providing an Integrated R&D Experience with Capabilities from Over 25 Inaugural Partners
2/28/2024
Ginkgo Bioworks announced the creation of the Ginkgo Technology Network - a groundbreaking ecosystem of cutting edge technology partners, each committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer R&D programs.
-
Ginkgo Bioworks Acquires Reverie Labs Platform, Enhancing AI-Driven Drug Discovery Capabilities for Customer Programs
2/28/2024
Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of key assets of Reverie Labs, which built and used AI/ML tools to accelerate drug discovery. Ginkgo has acquired Reverie's infrastructure and software for training large-scale AI foundation models.
-
Ginkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its Customers
2/28/2024
Today, Ginkgo Bioworks announced the acquisition of Proof Diagnostics, an innovative life sciences tools, diagnostics and computational discovery company which uncovered genome engineering tools for both therapeutic and diagnostics applications.
-
Ginkgo Bioworks Acquires Patch Biosciences, Expanding Suite of Genetic Medicine Capabilities Available to Customers
2/28/2024
Today, Ginkgo Bioworks announced the acquisition of Patch Biosciences, which has built an AI platform for sequence design that enables more effective, specific, and durable genetic medicines.
-
Form Bio and Ginkgo Partner to Develop Industry-Leading Solutions for AAV Gene Therapy Design and Development
2/28/2024
Form Bio and Ginkgo Bioworks today announced a new partnership to provide a complete and holistic solution offering for AAV gene therapy design and development.
-
Ginkgo Biosecurity Launches Doha-Based Pathogen Monitoring Center, CUBE-D, Establishing Middle East Hub for Global Bioradar, at Qatar Free Zones
2/27/2024
Ginkgo Bioworks has announced the signing of an agreement with Qatar Free Zones Authority and Doha Venture Capital to build the first Center for Unified Biosecurity Excellence in Doha within Qatar Free Zones.
-
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2023 Results Presentation
2/22/2024
Ginkgo Bioworks today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, beginning at 5:30 p.m. ET.
-
Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design
2/15/2024
The Defense Threat Reduction Agency's Joint Science and Technology Office for the Chemical and Biological Defense Program has awarded, through the Medical CBRN [Chemical, Biological, Radiological, and Nuclear] Defense Consortium requirement 22-05, "Adjuvant Activity to Vaccines Prototype," a 5-year contract totaling up to $31 million including program options to the team of Ginkgo Bioworks, Inc.
-
House Select Committee Tours Ginkgo Bioworks, Previews Biofab1, Ginkgo's New Integrated Data Generation Facility Set to Launch in 2025
2/13/2024
Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, hosted members of Congress focused on strengthening the U.S. bioeconomy in service of national and economic security yesterday.
-
Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world
1/15/2024
Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced that it has entered into a Co-Marketing Agreement with Illumina, Inc., a global leader in DNA sequencing and array-based technologies, to partner on expanding biosecurity capabilities globally.
-
Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference
1/10/2024
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced preliminary performance updates for the year ended December 31, 2023.
-
Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board
1/8/2024
f, which is building the leading platform for cell programming and biosecurity, announced the formation of its new Biopharma Advisory Board.
-
Ginkgo Bioworks Completes Program with Biogen to Boost Productivity of Gene Therapy Manufacturing Platform
1/4/2024
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the successful completion of the gene therapy collaboration they announced with Biogen in May 2021.
-
Ginkgo Bioworks Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45 a.m. PT (12:45 p.m. ET).
-
OneOne Biosciences Partners with Ginkgo Bioworks to Advance its Platform and Nitrogen Fixation Microbial Product
12/20/2023
OneOne Biosciences, a French startup building a comprehensive suite of agricultural microbial solutions for farmers, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership.
-
U.S. Department of Energy Awards Team Led by Ginkgo Bioworks Funding to Develop Algal Crop Protection Solutions
12/19/2023
Ginkgo Bioworks announced that a Ginkgo-led team — including partners from the Pacific Northwest National Laboratory, Colorado School of Mines, and Global Algae Innovations — has been awarded funding through the U.S. Department of Energy's Bioenergy Technologies Office.
-
FGen AG, a Ginkgo Bioworks Subsidiary, Awarded Funding Through European Innovation Council's Pathfinder Programme For Sustainable Milk Protein Production Project
12/19/2023
FGen AG, a subsidiary of Ginkgo Bioworks, based in Switzerland, has been awarded funding through the European Innovation Council's Pathfinder Challenge program.
-
Ginkgo Bioworks Receives Grant to Develop Innovative Live Cell Delivery Platform of Antibody Therapeutics for Treating HIV and Malaria
12/13/2023
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, has received a grant from the Bill & Melinda Gates Foundation to develop a novel cell-based technology for improving protein therapeutics delivery for patients in low- and middle-income countries (LMICs).
-
Arbor Biotechnologies Announces Collaboration with Ginkgo Bioworks to Advance the Discovery and Development of Precision Gene Editors
12/12/2023
Arbor today announced a collaboration with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, to leverage Ginkgo's comprehensive Codebase and automated Foundry to jointly optimize Arbor's novel precision editors.